In 1901, 51-year-old Auguste Deter sat in her room, anxiously looking around. Her new doctor, Alois Alzheimer, was asking her to identify mundane objects–but for some reason she couldn’t remember which ones she had already named.

Notes from this initial meeting paint a vivid picture of her condition, now called Alzheimer’s disease. More than 100 years later, it would be reclassified as early-onset Alzheimer’s disease. Deter is one of modern medicine’s most famous patients, but few people recognize her particular form of Alzheimer’s. So, how are early and late-onset Alzheimer’s different?

Before we dive in, let’s see what you know with a pop quiz. 

🤔What are the differences between early and late-onset Alzheimer’s disease?
(Note: There may be more than one right answer!)

A. Early and late-onset Alzheimer’s have mostly the same symptoms; however, early-onset develops before age 65 and late-onset develops after age 65.

B. Early-onset comes in two forms, either familial or sporadic while Late-onset is sporadic.

C. One form of Early-onset Alzheimer’s can be caused by variants in the APP, PSEN1, or PSEN2 genes. Late-onset Alzheimer’s disease is linked to a number of variants with the most well-known occurring in the APOE gene.

 

Think you found the right answer(s)? Continue reading to find out.

Worldwide, more than 30 million people have been diagnosed with some form of Alzheimer’s disease, affecting their memory and ability to conduct everyday tasks1. In the case of Auguste Deter, her disease caused her to have difficulty remembering her full name, the names of ordinary objects, and even the questions she was being asked [2]. These symptoms are typical for patients with advanced Alzheimer’s—both early and late-onset. The two are virtually indistinguishable in their effect on a person’s mental abilities. In fact, both forms of the disease have incredibly similar impacts on patient behavior and on cells in the brain.

On the cellular level, both early and late-onset Alzheimer’s disease are characterized by the buildup of a toxic protein fragment called amyloid beta (Aβ) and the appearance of unusual protein bundles called neurofibrillary tangles [1,3]. These changes are accompanied by progressive neuronal death and onset of Alzheimer’s.

Dedicated efforts have given us the ability to predict the odds of developing Alzheimer’s

Exactly what causes the buildup of these toxic elements has been the topic of intense research since they were first described by Dr. Alzheimer—observed in the brain of Auguste Deter after she had died—in the early 1900s. More than a century of research has shown us that there are two types of Alzheimer’s disease which can initially be distinguished by the age of diagnosis: Early-onset can manifest between the ages of 25 and 65, though most are not diagnosed before the age of 40 [4]. Late-onset develops in people at, or over, the age of 65. Research has also shown us that genetics does play a role, and this is where early-onset and late-onset Alzheimer’s begin to differentiate.

Approximately 4-6% of all Alzheimer’s disease cases are early-onset, meaning they occur at ages younger than 65. A subset of early-onset called early-onset familialAlzheimer’s disease (eFAD) represents only about 1% of all Alzheimer’s disease cases. Genetic studies have identified multiple genes associated with this form, including Amyloid Precursor Protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2). Variants in these genes are known to be highly penetrant, meaning people who inherit variants in them are very likely to develop symptoms of Alzheimer’s [4]. Fortunately, most people with Alzheimer’s do not have early-onset familial Alzheimer’s disease. Most cases of Alzheimer’s disease are the sporadic form, and typically occur past the age of 65 (late-onset).

For the most part, people who have Alzheimer’s disease have what’s known as sporadicAlzheimer’s, which can be either the early-onset (before age 65) or late-onset (after age 65) type. The sporadic form of the disease is generally not considered heritable in the same way that early-onset familial Alzheimer’s disease is. To understand this, it’s important to point out some of the differences in how genetics may contribute to both forms of the disease.

Other factors in late-onset Alzheimer’s

Knowing that sporadic Alzheimer’s disease is complex, researchers have studied both genetic and non-genetic factors that may predispose a person to late-onset disease. These efforts have shown us that a person’s age, sex, ethnicity, and environment can all affect their odds of developing Alzheimer’s.

Additionally, researchers have found variants in numerous genes that can be analyzed together to try to improve accuracy when predicting a person’s odds of disease development based on their genetics [1,3,4]

Numerous variants (changes in the DNA sequence) affecting different genes have been linked with sporadic late-onset Alzheimer’s—the most famous of which occur in the APOE gene. A specific version of the APOE gene, APOEϵ4, is known to be associated with a significant increase in risk for developing late-onset Alzheimer’s (from 1.8% odds of developing it for people aged 75 in the general public, to approximately 28% in people with two copies of APOEϵ4) and has been implicated as a risk factor for sporadic early-onset Alzheimer’s as well [5]. These numbers highlight two important points about the genetics of late-onset Alzheimer’s: Inheriting APOEϵ4 does not guarantee that you will develop Alzheimer’s, and it’s possible to develop this form of Alzheimer’s even if you haven’t inherited APOEϵ4. To put it another way, there are other (currently unknown) factors involved in development of Alzheimer’s that go beyond genetics.

More than 100 years after Dr. Alzheimer initially described Auguste’s disease, researchers sequenced her DNA and found a genetic variant in the PSEN1 gene that likely caused her disease [6]. The early age of onset (before the age of 65) and the potential existence of a variant in PSEN1 are very characteristic of early-onset familial Alzheimer’s. Researchers are continuing to study both forms of the disease with hopes of figuring out how variants in genes like PSEN1 or APOE may cause such dramatic effects and potentially developing cures based on this information.

These dedicated efforts have given us the ability to combine a person’s DNA sequence with information about their lifestyle to help predict their risk of developing Alzheimer’s. To that end, Helix now offers a product from ADx Healthcare which helps determine a person’s risk of developing late-onset (sporadic) Alzheimer’s based on which version of the APOE gene they have inherited. Combining these results with genetic counseling, this product aims to help people understand if they are at an increased risk of sporadic late-onset Alzheimer’s and what steps they may take to delay it.

👍Pop quiz answer: If you picked any answer, you were right! Each of these answers describes differences between the two forms of Alzheimer’s. ADx Healthcare will soon be offering a product that assesses a person’s risks for developing late-onset Alzheimer’s disease. To understand these differences, zoom back up to the article and learn about one of the world’s most common diseases.

References

1. Bekris, Lynn M. et al. “Genetics of Alzheimer Disease.” Journal of geriatric psychiatry and neurology 23.4 (2010): 213–227. PMC. Web. 10 Aug. 2018.

2. Maurer, K, et al. “Auguste D and Alzheimer’s Disease.” Advances in Pediatrics., U.S. National Library of Medicine, 24 May 1997, www.ncbi.nlm.nih.gov/pubmed/9167474.

3. Liu, Chia-Chen et al. “Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms, and Therapy.” Nature reviews. Neurology 9.2 (2013): 106–118. PMC. Web. 1 Aug. 2018.

4. Bird, Thomas D. “Early-Onset Familial Alzheimer Disease.” Advances in Pediatrics., U.S. National Library of Medicine, 18 Oct. 2012, www.ncbi.nlm.nih.gov/books/NBK1236/.

5. Genin, Emmanuelle et al. “APOE AND ALZHEIMER DISEASE: A MAJOR GENE WITH SEMI-DOMINANT INHERITANCE.” Molecular psychiatry 16.9 (2011): 903–907. PMC. Web. 10 Aug. 2018.

6. Müller, Ulrich, et al. “A Presenilin 1 Mutation in the First Case of Alzheimers Disease.” The Lancet Neurology, vol. 12, no. 2, 2013, pp. 129–130., doi:10.1016/s1474-4422(12)70307-1.

7. “Alzheimer Disease – Genetics Home Reference – NIH.” U.S. National Library of Medicine, National Institutes of Health, ghr.nlm.nih.gov/condition/alzheimer-disease.